Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD and Food Effect Study of TBD11 in Healthy Adults
NCT06707142Phase 1Completed
- Sponsor
- Gates Medical Research Institute
- Start
- Dec 2024
- Primary completion
- Feb 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing TBD11 with Placebo (2 arms). Primary endpoints: Incidence of treatment emergent adverse events and serious adverse events, Number of participants with clinically significant changes from Baseline in clinical laboratory values and 2 more. Started Dec 2024; status: completed.
02
Drugs
Tat-beclin 1 D11
Beyond the preview
Go deeper on NCT06707142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06707142.